Infertility specialist OvaScience has appointed Harald Stock, CEO of German pharma firm Grünenthal, to its board of directors.
Stock, who has served in his position at Grünenthal since 2009, will provide US-based OvaScience with strong working knowledge of the European pharma market as the company looks to expand its global reach.
“The global fertility market is nearly 10 times larger than the US alone, and growing rapidly,” said Dr Michelle Dipp, CEO of OvaScience.
“Harald's expertise and success commercialising products in global healthcare markets will be important to OvaScience as we advance our ex-US strategy.”
Prior to joining Grünenthal, Stock was chairman and managing director of the German DePuy Group, the orthopaedics division of Johnson & Johnson.
He has also spent time with Roche, serving in a variety of senior positions, including senior VP of its global near patient testing business.
In addition, Stock is a board member of EFPIA and previously represented J&J on the board of BVMed, the body representing the medical technology industry in Germany.